Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07941531
PHASE1

T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.

Sponsor: St. Jude Children's Research Hospital

View on ClinicalTrials.gov

Summary

Primary Objective: To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives: To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

Key Details

Gender

All

Age Range

Any - 21 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-12

Completion Date

2034-12

Last Updated

2026-11-19

Healthy Volunteers

No

Interventions

DRUG

Fludarabine

Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.

DRUG

Cyclophosphamide

Day -2 at 90mg/m2 dose. Intravenous infusion.

DEVICE

CliniMACS

CD7-CAR T-cell infusion

DRUG

Mesna

Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.

Locations (1)

St. Jude Children's Research Hospital

Memphis, Tennessee, United States